| Literature DB >> 22808002 |
Michala V Rose1, Godfather Kimaro, Thomas N Nissen, Inge Kroidl, Michael Hoelscher, Ib C Bygbjerg, Sayoki G Mfinanga, Pernille Ravn.
Abstract
AIM: To determine whether QuantiFERON®-TB Gold In-Tube (QFT) can contribute to the diagnosis of active tuberculosis (TB) in children in a high-burden setting and to assess the performance of QFT and tuberculin skin test (TST) in a prospective cohort of TB suspect children compared to adults with confirmed TB in Tanzania.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22808002 PMCID: PMC3395691 DOI: 10.1371/journal.pone.0037851
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Summary of recruitment and diagnostic classification of children.
* Children without follow-up data were excluded since they could not be classified according to the TB classifications. However one child had culture confirmed TB and could therefore be classified without follow-up data. ** The first 61 QFT results were excluded, when the initial QFT analysis showed very poor response in all the QFT tubes, including the mitogen. This was attributed to incorrect storage in a room reaching temperatures above 30°C. Subsequent tubes were all stored at 5–10°C.
Characteristics of study population.
| Children all | Confirmed | Possible | Not TB | Adults | ||||||
| N = 211 | N = 33 | N = 85 | N = 93 | N = 90 | ||||||
|
|
|
| 4.7 | (3.7) | 4.1 | (3.9) | 4.5 | (3.7) |
|
|
|
| ||||||||||
| <2 yrs |
|
| 7 | (21) | 36 | (42) | 34 | (37) |
|
|
| 2–4.9 yrs |
|
| 13 | (40) | 21 | (25) | 19 | (20) |
|
|
| 5–9.9 yrs |
|
| 8 | (24) | 15 | (18) | 28 | (30) |
|
|
| >10 yrs |
|
| 5 | (15) | 13 | (15) | 12 | (13) |
|
|
|
|
|
| 24 | (73) | 47 | (55) | 53 | (57) |
|
|
|
|
|
| 18 | (55) | 38 | (45) | 22 | (24) |
|
|
|
|
|
| 15 | (47) | 45 | (63) | 49 | (58) |
|
|
|
|
|
| – | – | – | – | – | – |
|
|
|
|
|
| 13 | (39) | 30 | (36) | 29 | (32) |
|
|
|
|
|
| 30 | (91) | 81 | (95) | 85 | (91) |
|
|
|
|
|
| 28 | (85) | 75 | (88) | 89 | (96) |
|
|
|
|
|
| 33 | (100) | 43 | (51) | 0 | 0 |
|
|
|
| ||||||||||
| Healthy |
|
| 31 | (97) | 28 | (33) | 93 | (100) |
|
|
| Still ill |
|
| – | – | 19 | (22) | 0 | 0 |
|
|
| Dead |
|
| 1 | (3) | 38 | (45) | 0 | 0 |
|
|
HIV test result available for 209 children, weight-for-age Z-score data available for 188 children, history of contact data available for 208 children (reported contact to case of TB in last 2 years), 1 child with confirmed TB did not have follow-up data (follow-up status defined as health status of child 6 months after inclusion into study).
Clinical TB in children defined as active TB diagnosed by local physician based on clinical examination, CXR and TST. Clinical TB in adults defined as active TB diagnosed by local physician, all included adults had positive Ziehl-Neelsen smear microscopy as well as either positive culture and/or positive fluorescence microscopy.
Median IFN-γ U/ml in all three Quantiferon TB Gold In-Tube tubes in children and adults.
| Children | Negative control | Positive control | TB antigens |
| IFN-γ U/ml (IQR) | IFN-γ U/ml (IQR) | IFN-γ U/ml (IQR) | |
| All (TB suspect) | 0.15* (0.09–0.35) | 2.05* (0.6–7.53) | 0.19* (0.1–0.55) |
| Confirmed TB | 0.15* (0.12–0.26) | 3.8 (1.08–7.26) | 0.17* (0.10–0.48) |
| Possible TB | 0.13* (0.08–0.27) | 1.69* (0.44–7.33) | 0.17* (0.10–0.56) |
| Not TB | 0.19* (0.09–0.38) | 2.26 (0.80–7.61) | 0.19* (0.11–0.55) |
|
| |||
| Confirmed TB | 0.36 (0.22–0.59) | 2.63 (1.29–8.09) | 3.28(0.99–6.58) |
Comparison of median IFN-γ values in the three QFT tubes in children and adults according to diagnostic TB classificaiton. There were significantly lower levels* (p<0.05) in all subgroups of children compared to adults, except in the positive control where median levels in children with confirmed and not TB were not significantly different to levels in adults.
Wilcoxon’s rank-sum test used to test difference between median IFN-γ in children and adults.
IQR: interquartile range.
Comparison of median IFN-γ responses in all TB suspect children.
| Negative control | Positive control | TB antigens | |||||
| IFN-γ U/ml (IQR) | p-value | IFN-γ U/ml (IQR) | p-value | IFN-γ U/ml (IQR) | p-value | ||
|
| <2 yrs | 0.14 (0.07–0.21) | – | 1.32 (0.4–8.05) | – | 0.14 (0.08–0.35) | – |
| ≥2 yrs | 0.16 (0.1–0.44) | 0.01 | 2.37 (1.01–7.33) | 0.09 | 0.21 (0.12–0.64) | 0.01 | |
|
| Male | 0.17 (0.09–0.45) | – | 2.18 (0.73–7.54) | – | 0.21 (0.12–0.57) | – |
| Female | 0.14 (0.09–0.24) | 0.08 | 1.48 (0.49–7.53) | 0.27 | 0.15 (0.09–0.39) | 0.04 | |
|
| Pos | 0.14(0.09–0.24) | – | 1.4 (0.47–5.61) | – | 0.15 (0.09–0.29) | – |
| Neg | 0.17 (0.09–0.52 | 0.09 | 2.49 (0.8–8.89) | 0.07 | 0.2 (0.1–0.84) | 0.01 | |
|
| ≤−2 | 0.14 (0.09–0.37) | – | 1.75 (0.6–6.46) | – | 0.18 (0.09–0.49) | – |
| >–2 | 0.15 (0.09–0.45) | 0.45 | 2.49 (0.78–9–87) | 0.32 | 0.21 (0.11–0.79) | 0.20 | |
|
| yes | 0.17 (0.10–0.–36) | 2.48 (0.99–7.39) | 0.19 (0.10–0.56) | |||
| no | 0.15 (0.09–0.37) | 0.56 | 1.77 (0.53–8.18) | 0.37 | 0.19 (0.10–0.54) | 0.77 | |
|
| yes | 0.12 (0.1–0.25) | 1.91 (0.63–4.35) | 0.17 (0.09–0.55) | |||
| no | 0.15 (0.09–0.37) | 0.51 | 1.77 (0.53–8.18) | 0.51 | 0.19 (0.1–0.54) | 0.79 | |
|
| yes | 0.15 (0.10–0.41) | 2.28 (0.73–7.45) | 0.18 (0.1–0.56) | |||
| no | 0.15 (0.08–0.34) | 0.69 | 1.91 (0.52–7.53) | 0.56 | 0.19 (0.1–0.53) | 0.68 | |
|
| Healthy | 0.16(0.09–0.39) | – | 2.65 (0.95–8.8) | – | 0.19(0.11–0.55) | – |
| Ill | 0.16 (0.08–0.35) | 0.59 | 1.08 ((0.33–2.68) | 0.04 | 0.24 (0.1–0.58) | 0.37 | |
| Died | 0.11 (0.05–0.2) | 0.01 | 1.02 (0.19–4.39) | <0.01 | 0.15 (0.07–0.4) | 0.18 | |
Comparison of median IFN-γ in subgroups of children, finding lower median levels in response to specific TB antigens in children <2 years, girls and HIV infected and lower median mitogen responses in children who subsequently died.
Wilcoxon’s rank-sum test used to test differences in median IFN-γ between subgroups of children, p<0.05 considered significant.
IQR: interquartile range.
Living PTB+ defined as living in the same household as a person with smear positive pulmonary TB.
Clinically diagnosed with TB and put on anti-TB therapy.
Subcategory “healthy” used for comparison both for “ill” and “died”.
Sensitivity of Quantiferon TB Gold In-Tube test and Tuberculin Skin test in children and adults.
| QFT positive | TST positive | p-value | |||||
| Children | n/all tested | (%) | 95% CI | n/all tested | (%) | 95% CI | |
| Clinical TB diagnosis | 11/60 | (18.3) | 8.4–28.3 | 8/69 | (11.6) | 3.9–19.3 | 0.28 |
| Confirmed TB | 5/27 | (18.5) | 3.4–33.6 | 2/31 | (6) | −2.4–15.3 | 0.16 |
| Possible TB | 14/59 | (23.7) | 12.7–34.8 | 7/77 | (9.1) | 2.6–15.6 | 0.02 |
| Not TB | 7/68 | (10.3) | 3.0–17.6 | 3/89 | (3.4) | −0.4–7.2 | 0.03 |
|
| |||||||
| Confirmed TB | 73/87 | (83.9) | 76.0–91.8 | 63/74 | (85.1) | 76.8–93.4 | 0.85 |
Sensitivity of QFT and TST according to TB status in children and adults, showing low sensitivity of both T-cell based test in children, irrespective of TB classification, compared to adults with confirmed TB.
Sensitivity analysis of QFT excludes indeterminate results.
Difference between sensitivity in QFT and TST tested using two-sample test of proportion.
Risk factors association with positive QFT results in children.
| QFT positive (n) | ||||||
| (N) | n/N (%) | OR (95% CI) | p-value | Adj OR1 (95% CI) | p-value | |
|
| ≥2 yrs | 17/105 (16.2) | 1 | – | 1 | – |
| <2 yrs | 9/49 (18.4) | 1.16 (0.48–2.84) | 0.73 | 0.93 (0.34–2.58) | 0.89 | |
|
| Female | 11/62 (17.7) | 1 | – | 1 | – |
| Male | 15/92 (16.3) | 0.90 (0.38–2.12) | 0.82 | 0.95 (0.37–2.43) | 0.92 | |
|
| Neg | 19/99 (19.2) | 1 | – | 1 | – |
| Pos | 6/54 (11.1) | 0.53 (0.20–1.41) | 0.20 | 0.61 (0.21–1.77) | 0.37 | |
|
| >−2 | 11/60 (18.3) | 1 | – | 1 | – |
| ≤−2 | 13/76 (11.9) | 0.92 (0.38–2.23) | 0.69 | 1.00 (0.39–2.59) | 0.99 | |
|
| No | 15/93 (16.1) | 1 | – | 1 | – |
| Yes | 11/60 (18.3) | 1.17 (0.50–2.75) | 0.72 | 1.37 (0.55–3.41) | 0.49 | |
|
| No | 15/93 (16.3) | 1 | – | 1 | – |
| Yes | 7/27 (25.9) | 1.82 (0.65–5.06) | 0.25 | 2.83 (0.89–9.03) | 0.08 | |
Risk factor analysis using logistic regression analysis found no association between known risk factors and a positive QFT result in children.
OR: unadjusted odds ratio from univariable analysis.
Adj OR: adjusted odds ratio, adjusted for age, sex, HIV, z-score and contact TB case.
p-value for the odds ratios.
Compares living with a case of smear positive TB case to those reporting no contact at all.
Risk factors association with indeterminate QFT results in children.
| QFT indeterminate (n) | ||||||
| (N) | n/N (%) | OR (95% CI) | p-value | Adj OR (95% CI) | p-value | |
|
| ≥2 yrs | 29/134 (21.6) | 1 | – | 1 | – |
| <2 yrs | 28/77 (36.4) | 2.07 (1.11–3.85) | 0.02 | 2.39 (1.22–4.68) | 0.01 | |
|
| Female | 25/87 (28.7) | 1 | – | 1 | – |
| Male | 32/124 (25.8) | 0.86 (0.47–1.59) | 0.64 | 0.79 (0.40–1.54) | 0.49 | |
|
| Neg | 32/131 (24.4) | 1 | – | 1 | – |
| Pos | 24/78 (30.8) | 1.38 (0.74–2.57) | 0.32 | 1.28 (0.63–2.63) | 0.50 | |
|
| >−2 | 19/79 (24.1) | 1 | – | 1 | – |
| ≤−2 | 33/109 (30.3) | 1.37 (0.71–2.65) | 0.35 | 1.09 (0.53–2.21) | 0.82 | |
Risk factor analysis using logistic regression analysis found increased odds of an indeterminate result in children <2 years.
OR: unadjusted odds ratio from univariable analysis.
Adj OR: adjusted odds ratio, adjusted for age, sex, HIV and z-score.
p-value for the odds ratios.
Risk factors association with positive QFT result in adults.
| QFT positive (n) | ||||||
| (N) | n/N (%) | OR (95% CI) | p-value | Adj. OR (95% CI) | p-value | |
|
| – | 1.0 (0.96–1.04) | 0.93 | 0.10 (0.95–1.04) | 0.89 | |
|
| Female | 11/16 (68.8) | 1 | 1 | ||
| Male | 62/71 (87.3) | 3.13 (0.88–11.12) | 0.08 | 2.07 (0.49–8.81) | 0.33 | |
|
| Neg | 57/63 (90.5) | 1 | 1 | ||
| Pos | 16/24 (66.7) | 0.21 (0.06–0.70) | 0.01 | 0.25 (0.07–0.92) | 0.04 | |
|
| ≥18.5 | 28/33 (84.9) | 1 | 1 | ||
| <18.5 | 45/54 (83.3) | 0.89 (0.27–2.94) | 0.85 | 0.81 (0.23–2.84) | 0.74 | |
Risk factor analysis using logistic regression analysis found lower odds of a positive QFT result in HIV infected adults.
OR: odds ratio from univariable analysis.
Adj. OR: adjusted odds ratio adjusted for age, sex, HIV infection and BMI.
Odds ratio calculated as per year increase in age.
p-value for the odds ratios.
Risk factors association with indeterminate QFT result in adults.
| QFT indeterminate (n) | ||||||
| (N) | n/N (%) | OR (95% CI) | p-value | Adj. OR (95% CI) | p-value | |
|
| – | 1.06 (0.99–1.15) | 0.10 | 1.10 (0.99–1.22) | 0.07 | |
|
| Female | 2/18 (11.1) | 1 | – | 1 | – |
| Male | 1/72 (1.4) | 0.11 (0.01–1.32) | 0.08 | 0.02 (0.00–1.28) | 0.07 | |
|
| Neg | 2/65 (3.1) | 1 | – | 1 | – |
| Pos | 1/25 ((4) | 1.31 (0.11–15.15) | 0.83 | 0.47 (0.01–17.02) | 0.68 | |
|
| ≥18.5 | 0/33 | – | – | – | – |
| <18.5 | 3/57 (5.3) | – | – | – | – | |
Risk factor analysis using logistic regression analysis found no association between suspected risk factors and an indeterminate QFT result in adults.
OR: odds ratio from univariable analysis.
Adj. OR: adjusted odds ratio adjusted for age, sex, HIV infection and BMI.
Odds ratio calculated as per year increase in age.
Logistic regression analysis not possible for association between BMI and indeterminate result, since there are no indeterminate results in those with BMI ≥18.5.
p-value for the odds ratios.
Figure 2Childhood mortality according to Quantiferon TB Gold In-Tube result.
Childhood mortality recorded during admission and at 6 month follow-up, according to QFT results. Children who did not attend scheduled follow-up at 6 months were traced and follow-up visits were conducted in their homes within 7–12 months of inclusion. Both the mortality during admission and the overall mortality in children with an indeterminate QFT result was significantly higher than in children with a determinate QFT result, p<0.001. * One of 154 children with a determinate QFT result did not have follow-up data.